Beijing Lidakang Technology
Manufacturer of artificial body joints
About Beijing Lidakang Technology
Beijing Lidakang Technology Co., Ltd. operates as a specialized entity in the Chinese orthopedic implant market, focusing on the research, development, production, and sale of artificial joints. The company was established in 1998 by Xu Yingchen, a senior engineer with a background in developing artificial joints at the former Iron and Steel Research Institute. This foundation built upon earlier work from 1983, when his team successfully developed a coral-surface microporous hip joint system that received a national science and technology award.
The company's business model is centered on providing a comprehensive portfolio of joint replacement solutions directly to healthcare institutions. It generates revenue through the sale of these medical devices. The product line is extensive, covering hip, knee, shoulder, and elbow joints, including solutions for initial implantation, revision surgeries, and complex tumor-related cases. Lidakang holds numerous product registrations for Class I, II, and III medical devices and has obtained CE certification for its hip, knee, shoulder, and elbow products, in addition to ISO 9001 and ISO 13485 quality management system certifications. A key offering is the tantalum-coated biological fixation femoral stem, which was the first of its kind to be domestically produced in China.
Significant milestones for the company include a Series A funding round of $16.4 million in January 2019, led by Shenzhen Capital Group and Lotus Lake Capital Management. In 2018, to meet growing demand, Lidakang launched a new 8,000-square-meter production and research base in Beijing's Shunyi District, capable of producing 100,000 sets of joint products annually. The company also engages in industry education, having established Lidakang College in 2015 in collaboration with orthopedic experts to provide training for medical professionals. More recently, Lidakang has ventured into advanced manufacturing techniques, including 3D printing to create custom-fit implants and is developing a joint surgery robot.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jan 2019 | $16M | $66M | Shenzhen Capital Group · Hetang Venture Capital Management (Beijing) | — |
Growth signals
Latest recorded traffic for Beijing Lidakang Technology is 60 monthly website visits, down 64.7% over the last three months. Beijing Lidakang Technology's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Beijing Lidakang Technology in the Dongcheng District ecosystem
The Beijing Lidakang Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Shenzhen Capital Group- H(Hetang Venture Capital Management (Beijing)
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Beijing Lidakang Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Beijing Lidakang Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










